Fulton and Marriottsville, MD

GLP-1 Weight Loss in Fulton and Marriottsville, MD

MedicationCompounded semaglutide

DosingWeekly subcutaneous injection

Program Length12 to 24 weeks typical

SupervisionProvider-led with lab review

A Refined Approach to GLP-1 Weight Loss

GLP-1 Weight Loss at Pura Vida Med Spa is a physician-supervised compounded semaglutide program that delivers once-weekly subcutaneous injections alongside structured provider check-ins, baseline labs, and lifestyle coaching - giving patients in Fulton and Marriottsville, MD a medically accountable path to sustained fat loss that over-the-counter supplements and diet plans alone cannot replicate. Semaglutide works by activating GLP-1 receptors in the brain to reduce appetite, slow gastric emptying, and regulate blood sugar, producing meaningful weight reduction in clinical trials across diverse patient populations. If diets and gym memberships have not delivered lasting results, our physician-supervised GLP-1 program can finally move the needle on your weight without crash dieting, surgery, or significant downtime.

At Pura Vida Med Spa, our Fulton and Marriottsville medical team personally oversees every GLP-1 patient from initial consultation through dose titration, lab review, and long-term maintenance planning, bringing the same evidence-based clinical standard to weight loss that we apply across all our wellness programs. Treatments are delivered at our 8110 Maple Lawn Blvd office and our 2470 Longstone Ln. suite, where our providers customize starting dose, titration schedule, and check-in cadence to your metabolism, comorbidities, and weight loss goals.

01 About
02 The Science
03 What We Treat
04 Benefits
05 Why Us
06 Compare

07 Treatment
08 Safety
09 Pricing
10 FAQs
11 References

Understanding GLP-1 Weight Loss

The science behind sustainable, medically supervised results

Traditional weight loss often fails because hunger, cravings, and slowed metabolism work against willpower. GLP-1 receptor agonists like semaglutide change the equation at a hormonal level. By mimicking the body's own glucagon-like peptide-1, the medication slows gastric emptying, blunts appetite signaling in the hypothalamus, and improves satiety after meals. The result is a natural reduction in caloric intake without the constant fight against hunger that derails most diets.

At Pura Vida, GLP-1 weight loss is more than a prescription. Our team pairs each weekly injection with baseline labs, blood pressure monitoring, and a structured titration schedule that minimizes side effects. We also coordinate with our hormone replacement therapy and IV therapy programs when appropriate, since metabolic health rarely improves in isolation. Patients in Fulton, Marriottsville, and surrounding Howard County communities work with our medical team to build a plan that supports the scale and the long view.

What Is GLP-1 Weight Loss?

GLP-1 weight loss uses injectable medications that act on the glucagon-like peptide-1 receptor, a hormone the gut releases after meals. Branded semaglutide is FDA approved for chronic weight management in adults with obesity or overweight plus a weight-related condition. Pura Vida Med Spa offers compounded semaglutide prescribed and supervised by our medical team.

It works on several fronts: slowing gastric emptying so meals stay longer, activating GLP-1 receptors in the hypothalamus to curb appetite, and improving insulin sensitivity. According to the National Institute of Diabetes and Digestive and Kidney Diseases, GLP-1 receptor agonists are among the most effective non-surgical tools for sustained weight reduction.

Treatment Timeline:

Treatment Time:

5 to 10 minutes per weekly visit or self-injection

First Signs:

Reduced appetite within 1 to 2 weeks

Full Effect:

12 to 24 weeks of progressive dose titration

Recovery:

No downtime, resume normal activities immediately

Concerns We Treat

Our GLP-1 program supports a range of metabolic and weight-related goals, from reducing appetite and cravings to improving blood sugar, for sustainable and medically supervised progress

Excess Body Weight

Sustained fat loss for adults with elevated BMI.

Persistent Hunger

Improved satiety and reduced food noise between meals.

Stalled Weight Loss

Breakthrough plateaus after diet and exercise plateau.

Insulin Resistance

Better post-meal glucose handling and metabolic markers.

Visceral Fat

Reduction in central adiposity linked to cardiovascular risk.

Emotional and Reactive Eating

Steadier appetite signals that help curb cravings and stress-driven snacking.

Real Weight Loss

Average 12 to 15 percent body weight reduction

Reduced Cravings

Quiets food noise and emotional snacking

Improvement

Better A1c, blood pressure, and lipid markers

Dosing

Once-weekly subcutaneous injection

Expert Oversight

Lab review, titration, and side-effect management

Feature	GLP-1 (Semaglutide)	Tirzepatide	HCG Diet	Diet and Exercise Alone	Bariatric Surgery	Phentermine
Typical Weight Loss	12 to 15 percent	15 to 20 percent	Modest, variable	5 to 10 percent	25 to 30 percent	5 to 10 percent
Dosing	Weekly injection	Weekly injection	Daily injection	Daily lifestyle	One-time procedure	Daily oral
Mechanism	GLP-1 receptor agonist	GLP-1 and GIP dual agonist	Calorie restriction with hormone	Caloric deficit	Anatomic restriction	Appetite suppression
Provider Oversight	Required, included here	Required, included here	Required	Optional	Surgical team	Required
Reversible	Yes	Yes	Yes	Yes	Mostly no	Yes
Best For	BMI 27+ with comorbidity or BMI 30+	Higher BMI or stalled GLP-1 response	Short-term jump-start	Mild excess weight	Severe obesity	Short-term use

Who Is a Good Candidate for GLP-1 Weight Loss

The ideal GLP-1 candidate is an adult who has tried diet and exercise without lasting results and meets medical criteria.

Ideal Candidates for GLP-1 Weight Loss

Adults with BMI of 30 or higher
Adults with BMI of 27 or higher and at least one weight-related comorbidity such as hypertension, prediabetes, type 2 diabetes, or dyslipidemia
Patients committed to weekly injections and provider check-ins
Adults who have not achieved durable results with diet and exercise alone

Who Should Wait or Avoid GLP-1 Weight Loss

Pregnancy, breastfeeding, or active family planning within the next 2 months
Personal or family history of medullary thyroid carcinoma or MEN 2 syndrome
History of pancreatitis or severe gastroparesis
Type 1 diabetes without endocrinology coordination

Talk to Us First If…

You have a personal or family history of medullary thyroid cancer or MEN2
You have a history of pancreatitis or significant GI issues
You take other glucose-lowering medications
You're pregnant, breastfeeding, or planning pregnancy soon

If you have any of the contraindications above, our medical team can discuss alternatives such as HCG diet or non-pharmacologic approaches.

Consultation and Labs

Our medical team reviews your history, BMI, and goals, then orders baseline labs including metabolic panel and A1c.

Program Design

We confirm candidacy, set a target dose range, and schedule your first injection along with weekly or monthly check-ins.

First Injection

You receive a low starting dose of compounded semaglutide via subcutaneous injection and learn at-home self-injection technique.

Titration and Monitoring

Doses are increased every 4 weeks based on tolerance and response, with side effects managed proactively.

Maintenance Planning

Once you reach your goal range, our team transitions you to a maintenance protocol that protects long-term results.

Side Effects and Risks

GLP-1 receptor agonists are well-studied.

Most side effects are gastrointestinal, dose-dependent, and tend to improve as your body adjusts. According to safety data summarized by the U.S. Food and Drug Administration, the most common adverse effects include nausea, diarrhea, vomiting, constipation, abdominal pain, fatigue, and headache. These are typically mild to moderate and most pronounced during dose escalation.

Less common but more serious risks include pancreatitis, gallbladder disease, acute kidney injury related to dehydration from vomiting, hypoglycemia (especially in patients on insulin or sulfonylureas), and rare allergic reactions.

Animal studies have shown thyroid C-cell tumors with GLP-1 agonists, leading to a boxed warning. Semaglutide is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. Our medical team manages side effects proactively. We slow the titration schedule if needed, recommend dietary adjustments to minimize nausea, and remain available by phone for any concerning symptoms. Call our office immediately for severe abdominal pain, persistent vomiting, signs of dehydration, or symptoms of pancreatitis.

GLP-1 Weight Loss Pricing

Transparent monthly pricing with financing available

Pura Vida Med Spa offers compounded semaglutide on a monthly program basis. Pricing reflects medication, supplies, baseline labs, all provider visits, and ongoing titration support. Insurance does not typically cover compounded GLP-1 medications, but we provide superbills for HSA and FSA reimbursement where applicable.

Program Pricing

Initial consultation and baseline labs: starting at $299
Monthly program (medication, supplies, and provider visits): starting at $399 per month
12-week starter package: starting at $1,099 (savings vs. monthly)
Maintenance dosing after goal weight: priced based on dose

Financing Options

Pura Vida Med Spa accepts CareCredit and Cherry Financing for qualified patients, making monthly payments accessible. Final pricing is confirmed at consultation based on your starting dose and program length.

To confirm your personalized GLP-1 program investment, call (301) 604-8432 or book a consultation online.

Physician Founded

Dr. Leslie Apgar, MD personally established our medical protocols.

Baseline Labs Included

Metabolic panel and screening before your first injection.

Personalized Titration

Doses adjusted to your tolerance and response, not a fixed script.

Two Convenient Locations

Maple Lawn in Fulton and our Marriottsville location serve all of Howard County.

Ongoing Check-Ins

Ongoing follow-ups keep you on track, flag side effects, and fine-tune your dose.

Body Composition Support

We pair GLP-1 programs with Emsculpt Neo to help you preserve muscle and lean out.

Tirzepatide

Advanced Dual-Action GLP-1 Weight Loss for Faster Results

Adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition
Patients who have not reached goals with lifestyle changes alone
Those who want a stronger, dual-pathway option compared to our GLP-1 weight loss program

HCG Diet

Structured HCG Program for Targeted Fat Loss

Adults seeking a structured, short-term, supervised weight loss framework
Patients who have stalled on conventional diet and exercise approaches
Those willing to follow a strict VLCD with weekly clinical check-ins

Hormone Replacement Therapy

Bioidentical HRT and Hormone Pellets for Women and Men

Women in perimenopause or menopause with hot flashes, night sweats, sleep changes, or vaginal dryness
Women with low libido, mood changes, or brain fog confirmed by hormone testing
Men with symptoms of low testosterone (fatigue, low libido, mood, body composition changes) plus lab confirmation

01 How much weight can I expect to lose on GLP-1?

In the pivotal STEP-1 trial, adults without diabetes lost an average of 14.9 percent of body weight at 68 weeks on semaglutide 2.4 mg, compared with 2.4 percent on placebo. Individual results vary based on starting BMI, dose tolerance, and lifestyle adherence. Most Pura Vida patients see meaningful weight loss within the first 12 weeks.

02 How quickly do GLP-1 injections start working?

Appetite reduction often begins within the first 1 to 2 weeks. Visible weight loss typically becomes apparent by week 4 to 6 as you titrate to a therapeutic dose. The full effect of GLP-1 weight loss is generally seen over 12 to 24 weeks of progressive titration.

03 Can I do GLP-1 injections at home?

Yes. After your first in-office injection and self-injection training, most patients administer their weekly dose at home. Our medical team remains available for questions, side-effect management, and scheduled check-ins throughout your program.

04 What happens if I stop taking GLP-1?

Weight regain is common if GLP-1 therapy is stopped abruptly without a maintenance plan. Our team builds a tapered transition or low-dose maintenance protocol to help protect your results. Continued attention to nutrition, sleep, strength training, and stress management is essential for long-term success.

05 Is compounded semaglutide safe?

Compounded semaglutide prescribed by a licensed physician and sourced from a reputable 503A or 503B compounding pharmacy is widely used in medical weight loss programs. Pura Vida only uses pharmacies that follow strict quality and sterility standards. Our medical team reviews your labs and history before prescribing to confirm candidacy.

06 Will GLP-1 work if I have already tried tirzepatide?

Many patients switch between GLP-1 medications based on tolerance, cost, and response. During your consultation, our team reviews your prior experience with tirzepatide and helps decide whether to continue with semaglutide or consider another approach such as our HCG diet program.

Fulton8110 Maple Lawn Blvd, Suite 145
Fulton, MD, 20759(301) 604-8432

Marriottsville2470 Longstone Ln., Suite C
Marriottsville, MD, 21104(410) 816-5173

Schedule Your GLP-1 Weight Loss Consultation

References

Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med 2021. PubMed (PMID: 33567185).
Davies M, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet 2021. PubMed (PMID: 33667417).
Wadden TA, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA 2021. PubMed (PMID: 33625476).
Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA 2021. PubMed (PMID: 33755728).
Sorli C, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Lancet Diabetes Endocrinol 2017. PubMed (PMID: 28110911).
Ahren B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin (SUSTAIN 2). Lancet Diabetes Endocrinol 2017. PubMed (PMID: 28385659).
Aroda VR, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3). Diabetes Care 2017. PubMed (PMID: 29030383).